Adcentrx begins patient dosing in phase 1a/b study of ADRX─0405, a potential first─in─class ADC targeting STEAP1 to treat advanced solid tumours

Adcentrx Therapeutics (Adcentrx), a clinical─stage biotechnology company advancing innovative protein conjugates for cancer and other life─threatening diseases, announced the first patient dosed in the phaseAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute